These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 19152342)
1. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342 [TBL] [Abstract][Full Text] [Related]
2. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699 [TBL] [Abstract][Full Text] [Related]
3. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572 [TBL] [Abstract][Full Text] [Related]
4. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404 [TBL] [Abstract][Full Text] [Related]
5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848 [TBL] [Abstract][Full Text] [Related]
7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
8. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246 [TBL] [Abstract][Full Text] [Related]
9. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645 [TBL] [Abstract][Full Text] [Related]
10. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738 [TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related]
13. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
14. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L; Giocanti N; Hennequin C; Favaudon V Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473 [TBL] [Abstract][Full Text] [Related]
15. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592 [TBL] [Abstract][Full Text] [Related]
16. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Sirotnak FM; She Y; Lee F; Chen J; Scher HI Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602 [TBL] [Abstract][Full Text] [Related]
17. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722 [TBL] [Abstract][Full Text] [Related]
18. PC-1/PrLZ contributes to malignant progression in prostate cancer. Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733 [TBL] [Abstract][Full Text] [Related]
19. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]